Xenetic Biosciences Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Jim Parslow
Chief Executive Officer (CEO)
US$433.7k
Compensación total
| Porcentaje del salario del CEO | 75.9% |
| Permanencia del CEO | 7.6yrs |
| Participación del CEO | n/a |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 5.3yrs |
Actualizaciones recientes de la dirección
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Recent updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Xenetic Biosciences reports Q2 results
Aug 12Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
Aug 02Xenetic inks clinical manufacturing contract with Catalent
Jul 07Xenetic Biosciences reports Q3 results
Nov 13Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$4m |
| Jun 30 2024 | n/a | n/a | -US$5m |
| Mar 31 2024 | n/a | n/a | -US$4m |
| Dec 31 2023 | US$434k | US$329k | -US$4m |
| Sep 30 2023 | n/a | n/a | -US$4m |
| Jun 30 2023 | n/a | n/a | -US$4m |
| Mar 31 2023 | n/a | n/a | -US$6m |
| Dec 31 2022 | US$474k | US$329k | -US$7m |
| Sep 30 2022 | n/a | n/a | -US$7m |
| Jun 30 2022 | n/a | n/a | -US$7m |
| Mar 31 2022 | n/a | n/a | -US$6m |
| Dec 31 2021 | US$521k | US$299k | -US$6m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$11m |
| Mar 31 2021 | n/a | n/a | -US$11m |
| Dec 31 2020 | US$359k | US$285k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$14m |
| Mar 31 2020 | n/a | n/a | -US$14m |
| Dec 31 2019 | US$388k | US$265k | -US$18m |
| Sep 30 2019 | n/a | n/a | -US$19m |
| Jun 30 2019 | n/a | n/a | -US$10m |
| Mar 31 2019 | n/a | n/a | -US$11m |
| Dec 31 2018 | US$288k | US$265k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$1m |
| Jun 30 2018 | n/a | n/a | -US$2m |
| Mar 31 2018 | n/a | n/a | -US$3m |
| Dec 31 2017 | US$960k | US$199k | -US$4m |
Compensación vs. Mercado: La compensación total de Jim($USD433.73K) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD646.00K).
Compensación vs. Ingresos: La compensación de Jim ha sido consistente con los resultados de la empresa en el último año.
CEO
Jim Parslow (59 yo)
7.6yrs
Permanencia
US$433,732
Compensación
Mr. James F. Parslow, also known as Jim, has been Chief Financial Officer at Xenetic Biosciences, Inc. since April 03, 2017 and serves as its Chief Operating Officer and Corporate Secretary and serves as i...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President & Director | 8.3yrs | US$563.49k | 0.027% $ 1.7k | |
| Independent Non Executive Director | less than a year | US$12.33k | 0% $ 0 | |
| Independent Director | 8.8yrs | US$57.54k | 0% $ 0 | |
| Independent Director | 10.8yrs | US$57.54k | 0% $ 0 | |
| Non-Executive Director | less than a year | sin datos | 4.44% $ 276.6k | |
| Member of Scientific Advisory Board | 5.5yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 5.8yrs | sin datos | sin datos | |
| Independent Director | 5.3yrs | US$57.54k | sin datos | |
| Independent Non-Executive Director | 5.2yrs | US$57.54k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.8yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.5yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2yrs | sin datos | sin datos |
5.3yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: La junta directiva de XBIO se considera experimentada (5.3 años de antigüedad promedio).